Amiodarone Exposure During Modest Inflammation Induces Idiosyncrasy-like Liver Injury in Rats: Role of Tumor Necrosis Factor-alpha

Jingtao Lu,*† A. Daniel Jones,*‡ Jack R. Harkema,†§ Robert A. Roth,†¶ and Patricia E. Ganey†¶†1

*Department of Biochemistry and Molecular Biology, †Center for Integrative Toxicology, ‡Department of Chemistry, §Department of Pathobiology and Diagnostic Investigation, and ¶Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824

1To whom correspondence should be addressed at Department of Pharmacology and Toxicology, Michigan State University, 214 Food Safety and Toxicology Building, East Lansing, MI 48824. Fax: (517) 432-2310. E-mail: ganey@msu.edu.

Received July 26, 2011; accepted September 30, 2011

Amiodarone [2-butyl-3-(3',5'-diiodo-4'-diethylaminoethoxybenzoyl)-benzofuran] (AMD), a class III antiarrhythmic drug, is known to cause idiosyncratic hepatotoxic reactions in human patients. One hypothesis for the etiology of idiosyncratic adverse drug reactions is that a concurrent inflammatory stress results in decreased threshold for drug toxicity. To explore this hypothesis in an animal model, male Sprague-Dawley rats were treated with nonhepatotoxic doses of AMD or its vehicle and with saline vehicle or lipopolysaccharide (LPS) to induce low-level inflammation. Elevated alanine aminotransferase (ALT), aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase activities as well as increased total bile acid concentrations in serum and midzonal hepatocellular necrosis were observed only in AMD/LPS-cotreated rats. The time interval between AMD and LPS administration was critical: AMD injected 16 h before LPS led to liver injury, whereas AMD injected 2–12 h before LPS failed to cause this response. The increase in ALT activity in AMD/LPS cotreatment showed a clear dose-response relationship with AMD as well as LPS. The metabolism and hepatic accumulation of AMD were not affected by LPS coexposure. Serum concentration of tumor necrosis factor-alpha (TNF) was significantly increased by LPS and was slightly prolonged by AMD. In Hepa1c17 cells, addition of TNF potentiated the cytotoxicity of both AMD and its primary metabolite, mono-N-desethylamiodarone. In vivo inhibition of TNF signaling by etanercept attenuated the AMD/LPS-induced liver injury in rats. In summary, AMD treatment during modest inflammation induced severe hepatotoxicity in rats, and TNF contributed to the induction of liver injury in this animal model of idiosyncratic AMD-induced liver injury.

Key Words: idiosardone hepatotoxicity; inflammation; lipopolysaccharide; idiosyncrasy adverse drug reactions; drug metabolism; tumor necrosis factor-alpha.

Idiosyncratic adverse drug reactions (IADRs) typically occur only in a small fraction of patients who are treated with certain drugs at therapeutic doses. IADRs are usually unrelated to the pharmacological target of the drug. They present a serious human health problem and are usually not predicted by current preclinical safety evaluation during drug development. During the period 1975–2000, 10% of newly approved drugs were withdrawn from the U.S. market or received black box warnings due to these adverse reactions (Roth et al., 2003; Uetrecht, 2007).

The mechanisms by which IADRs occur are not clear. Evidence from experimental animals indicates that mild inflammation can decrease the threshold for toxicity and thereby render an individual susceptible to an adverse drug reaction that would not otherwise occur (Roth et al., 2003). Lipopolysaccharide (LPS), a cell wall component of gram-negative bacteria, is widely used as an inflammagen in these animal studies. A nonhepatotoxic dose of LPS can interact with nontoxic doses of several IADR-associated drugs from different pharmacologic classes to induce liver damage in rodents (Deng et al., 2006; Luyendyk et al., 2003; Waring et al., 2006; Zou et al., 2009b).

Amiodarone [2-butyl-3-(3',5'-diiodo-4'-diethylaminoethoxybenzoyl)-benzofuran] (AMD), a class III antiarrhythmic drug, is effective in increasing the survival of patients after myocardial infarction or congestive heart failure (Singh, 1996). Since the approval of AMD by the U.S. Food and Drug Administration in 1985, the use of this drug has been associated with a variety of adverse effects, including liver dysfunction, pulmonary complications, thyroid dysfunctions, and ocular disturbance (Rotmensch et al., 1984). The reported frequency of liver abnormalities in patients receiving AMD varies from 14 to 82% (Lewis et al., 1989). Most of these reactions are mild, with serum transaminase elevation within threefold of the upper limit of normal (ULN), but some are more severe (Babatin et al., 2008). Cases of liver reactions after intravenous administration of AMD are rare, but damage can be acute and marked (Rätz Bravo et al., 2005). Fulminant hepatic failure or death associated with AMD hepatotoxicity has also been reported (Babatin et al., 2008).
There is evidence that the interaction between LPS-induced cytokines and drugs or their metabolites plays an important role in the LPS-drug interaction (Zou et al., 2009a). Tumor necrosis factor-alpha (TNF) is a proximal mediator of the inflammatory cascade induced by LPS (Beutler and Kruys, 1995) and is critically involved in many models of liver injury, such as ischemia/reperfusion (Teoh et al., 2004), alcoholic liver disease (Yin et al., 1999) and some drug/LPS-induced liver injury models (Shaw et al., 2009b; Tukov et al., 2007; Zou et al., 2009a). As an example, TNF selectively augmented the cytotoxicity of sulindac sulfide, which is the major toxic metabolite of sulindac (Zou et al., 2009a). In the case of amiodarone, the major metabolite of AMD is mono-N-desethylamiodarone (DEA), which shares similar pharmacological (Talajic et al., 1987) and pharmacokinetic (Shayeganpour et al., 2008) characteristics with AMD. DEA has antiarrhythmic properties, a very long half-life, and accumulates in the liver and many other tissues. In primary hepatocytes, HepG2 cells and other cell types, DEA is much more cytotoxic than AMD (Waldhauser et al., 2006). The plasma concentration of DEA is greater in cases of AMD-associated IADRs (O’Sullivan et al., 1995), suggesting a possible role for this metabolite in AMD toxicity.

The purpose of this study was to test the hypothesis that inflammatory stress induced by LPS potentiates amiodarone-induced hepatotoxicity in rats. When the results demonstrated a hepatotoxic interaction between inflammatory stress and amiodarone, the roles of metabolism and TNF were explored.

**MATERIALS AND METHODS**

**Materials.** Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich (St Louis, MO). The activity of LPS (Lot 075K4038, derived from *Escherichia coli* serotype O55:B5) was 3.3 × 106 endotoxin units (EU)/mg, which was determined by a Limulus Amebocyte Lysate Kinetic-QCL kit from Cambrex Corp. (Kit 50-650U; East Rutherford, NJ). The reagents for the measurement of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyltransferase (GGT) activities were purchased from Thermo Electron Corp. (Waltham, MA). The kit for total bile acids measurement was purchased from Diazyme Laboratories (Poway, CA).

**Animals.** Male Sprague-Dawley rats (Crl:CD(SD)IGS BR; Charles River, Portage, MI) weighing 250–370 g were used for in vivo studies. They were fed standard chow (Rodent Chow/Tek 8640; Harlan Teklad, Madison, WI) and allowed access to water ad libitum. Animals were allowed to acclimate for 1 week in a 12-h light/dark cycle prior to experiments. They received humane care according to the criteria in the Guide for the Care and Use of Laboratory Animals.

**Experimental protocol.** In all the experiments, rats were fasted for 12 h before administration of LPS and food was returned thereafter. A 20 mg/ml solution of AMD was made in its vehicle (0.18% Tween 80), and 4.1 × 105 EU/ml solution of LPS was made in sterile saline. To determine the optimal time interval between AMD and LPS treatments, rats were treated with AMD (300 mg/kg, ip) 2 h, 8 h, 12 h, 16 h, or 20 h before LPS (1.6 × 108 EU/kg, iv). For the evaluation of the dose-response relationship for AMD, rats were treated with AMD (0–400 mg/kg, ip) and 16 h later with LPS (1.6 × 106 EU/kg, iv) or saline. For the evaluation of the dose-response relationship for LPS, rats were treated with AMD (400 mg/kg, ip) or vehicle and 16 h later with LPS (0–1.6 × 106 EU/kg, iv). In subsequent studies, rats were treated with AMD (400 mg/kg, ip) or vehicle and 16 h later with LPS (1.6 × 106 EU/kg, iv) or saline. In the etanercept treatment study, rats were treated with etanercept (8 mg/kg) or sterile water by sc injection 1 h before LPS.

Rats were anesthetized with isoflurane, and blood and liver samples were taken. Serum was prepared from blood, and plasma was prepared from blood collected into a syringe containing 3.2% sodium citrate (BD Biosciences, San Diego, CA). The right medial lobe of the liver was rapidly frozen for immunohistochemistry, and the left lateral lobe of liver was fixed in 10% neutral-buffered formalin and stored in 70% ethanol for histopathology.

**Evaluation of liver injury.** Liver injury was estimated from the serum activities of ALT, AST, ALP, and GGT and from the serum concentration of total bile acids.

Formalin-fixed liver samples were embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) staining. The stained liver sections were examined using light microscopy.

**Drug and metabolite analysis.** Serum samples and liver homogenates were mixed with acetonitrile containing ethopropazine as internal standard (IS). After vortexing and centrifugation, protein was removed, and the supernatant was diluted and transferred to autosampler vials for liquid chromatography-tandem mass spectrometry (LC/MS/MS) analysis. LC/MS/MS analysis was performed by use of a Shimadzu LC-20 high performance liquid chromatography (HPLC) system coupled to a QTRAP 3200 tandem quadrupole mass spectrometer (AB SCIEX, Foster City, CA) operated under control of Analyst v. 1.4.2 software. The Ascentis Express C18 HPLC Column (5 cm × 2.1 mm, 2.7 μm) was maintained at 50°C. A volume of 2 μl was injected into the HPLC system and eluted with a gradient based on 10 mM ammonium acetate in H₂O (solvent A) and methanol (solvent B): 0–0.5 min, 10% solvent B; 0.5–1 min, 10–98% solvent B; 1–4 min, 98% solvent B; 4–6 min, 10% solvent B; flow rate, 0.3 ml/min. Positive mode electrospray ionization was used for all analyses. Mass spectrometry parameters, including declustering potential and collision energy, were optimized independently for each analyte and IS. Multiple reactions monitoring the m/z transitions were used for the quantitative analysis of AMD (m/z 646.1 → 201.1), DEA (m/z 618.1 → 547.0), and ethopropazine (m/z 313.1 → 114.1). The LC/MS/MS method achieved lower limits of quantification: ≤ 50 ng/ml for AMD and ≤ 5 ng/ml for DEA. Analytical reproducibility was judged to be ± 10.2% in the middle of the calibrated range of concentrations. The Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL) was used to determine protein concentration in the liver homogenates.

**Serum TNF concentration.** TNF concentration in serum was measured with an ELISA kit (BD Biosciences).

**Assessment of cytotoxicity in vitro.** The murine hepatoma cell line Hepa1c1c7 purchased from American Type Culture Collection (Manassas, VA) was used to assess cytotoxicity in vitro. Hepa1c1c7 cells were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) with 1% antibiotic-antimycotic (Invitrogen) and 10% heat-inactivated fetal bovine serum (SAFC Biosciences, Lenexa, KS) in 75-cm² tissue culture flasks at 37°C in a humidified atmosphere of 95% air and 5% CO₂. Cells were plated in 96-well plates at 15,000 cells per well and allowed to attach for 8 h before medium was replaced. Various concentrations of AMD, DEA, and/or TNF were added to designated wells, and cells were incubated under maintenance conditions. Twenty-four hours later, lactate dehydrogenase (LDH) activity released into the culture medium was measured using the Cytotox-One Homogeneous Membrane Integrity Assay (Promega, Madison, WI). The percent LDH release was calculated as LDH in supernatant/LDH in supernatant + LDH in cell lysate. Lysate LDH was determined after addition of Triton to lyse the cells.

**Statistical analysis.** The results are expressed as means ± SEM. One-way or two-way ANOVA was applied as appropriate; Tukey’s method was employed as a *post hoc* test. Grubb’s test was used to detect outliers. At least three biological replications were performed for each experiment. The *p* value < 0.05 was set as the criterion for statistical significance.
RESULTS

The Time Interval Between AMD and LPS Administration is Important for the Production of Liver Injury

Serum ALT activity did not increase from treatment with either LPS or AMD alone (Fig. 1). In the AMD/LPS group, administration of AMD at 16 or 20 h before LPS resulted in significant serum ALT activity increase, whereas AMD injected 2–12 h before LPS failed to cause this response. The 16-h interval between AMD and LPS treatments was selected for future studies.

Dose-Response Relationships and Time Course of Liver Injury

Neither AMD alone nor LPS alone affected ALT activity at any of the doses tested. In rats cotreated with AMD and LPS, serum ALT activity was dependent on both AMD (Fig. 2A) and LPS (Fig. 2B) doses. Significant increases in ALT activity were observed with AMD doses ≥ 300 mg/kg (p < 0.05) and with LPS doses ≥ 1.2 × 10^6 EU/kg (p < 0.05). 400 mg/kg and 1.6 × 10^6 EU/kg were selected as AMD and LPS doses for subsequent studies, respectively.

In the time course study, the serum activities of both ALT and AST were measured as markers for hepatocellular injury (Figs. 3A and B). Neither AMD nor LPS alone affected serum ALT activities at any time examined. For the AST activity, LPS alone had no effect at any time examined, and AMD alone caused a slight increase at 2, 4, and 10 h. Significant elevation of serum ALT and AST activities were only observed in AMD/LPS cotreatment, and the increases started between 4 and 6 h after LPS administration and continued to increase through 10 h.

At 10 h after LPS administration, serum activities of ALP and GGT and concentration of bile acids were measured as indicators of cholestatic injury (Figs. 4A–C). Only AMD/LPS cotreatment caused significant increases in these serum markers, whereas AMD or LPS treatment alone had no effect.

Hepatic Histopathology

All the saline-treated control rats were free of liver lesions (Fig. 5A). No microscopic evidence of hepatic pathology was found in four of the six LPS-treated rats (Fig. 5B). Liver sections from two of the LPS-treated rats had a few small foci of midzonal hepatocellular necrosis with an associated neutrophilic influx. In contrast, a widespread, mild-to-marked fibrinopurulent capsulitis was present in the liver sections from all the AMD-treated rats (Fig. 5C). This was characterized by a thickening of the hepatic capsule due to edema and a conspicuous inflammatory exudate comprising mainly neutrophils, lesser numbers of mononuclear cells, and various amounts of amorphous proteinaceous material. This fibrinopurulent exudate was also often scattered along the outer peritoneal surface of the capsule. Focal areas of subcapsular hepatocellular necrosis were occasionally associated with the capsulitis.

The most profound hepatic histopathology was found in animals treated with both AMD and LPS (Fig. 5D). All these rats had a mild-to-marked fibrinopurulent capsulitis with occasional subcapsular necrosis similar to that found in the AMD-treated rats, but in addition, all these animals had conspicuous areas of midzonal hepatocellular necrosis. The latter lesion ranged from widely scattered focal areas of necrosis in midzonal regions to widespread hepatocellular necrosis with coalescence of affected midzonal and occasionally centriacinar regions (bridging necrosis). Accumulations of neutrophils (inset, Fig. 5D) were present in all these necrotic regions. Periportal regions were spared of AMD/LPS treatment-related injury.

FIG. 1. Effect of time interval between AMD and LPS administrations on the induction of liver injury. Rats were treated with AMD (300 mg/kg, ip) 2, 8, 12, 16, or 20 h before LPS (1.6 × 10^6 EU/kg, iv). Serum ALT activity was measured 10 h after LPS injection. # and * indicate significantly different from AMD/Sal or Vehicle/LPS, respectively. p < 0.05, n = 3–8.

FIG. 2. Dose-response relationships for AMD and LPS. (A) Rats were treated with AMD (0–400 mg/kg, ip) and 16 h later with saline or LPS (1.6 × 10^6 EU/kg, iv). (B) Rats were treated with AMD (400 mg/kg, ip) or its vehicle and 16 h later with LPS (0–1.6 × 10^6 EU/kg, iv). Serum ALT activity was measured at 10 h after LPS administration for both data sets. # indicates significantly different from respective groups not given LPS; * indicates significantly different from respective group not given AMD. p < 0.05, n = 3–14.
LPS Did Not Affect the Metabolism or Hepatic Accumulation of AMD

AMD and DEA concentrations in rat serum and liver homogenates were determined at various times after LPS administration (Figs. 6A–D). From 2 to 10 h after LPS or saline administration (i.e., 18–28 h after AMD administration), the serum and tissue concentrations of AMD and DEA were unaffected by LPS cotreatment. The average serum concentrations of AMD and DEA were 1100 and 128 ng/ml, respectively; and the average liver concentrations of AMD and DEA were 157 and 53 ng/mg protein, respectively.

AMD Affected the Concentration of TNF in Serum

Serum TNF concentration was measured at 2 and 4 h after LPS administration (Fig. 7). AMD by itself had no effect on serum TNF concentration. At 2 h after LPS, the serum TNF concentrations in rats treated with AMD/LPS or with vehicle/LPS were similar. However, by 4 h after LPS, the concentration of TNF in serum of AMD/LPS-treated rats was significantly greater than that in vehicle/LPS-treated rats.

TNF Potentiated the Cytotoxicity of AMD and DEA in Hepa1c1c7 Cells

Hepa1c1c7 cells were exposed to AMD or DEA, and 24 h later, cytotoxicity was assessed by measuring LDH activity released into the culture medium (Figs. 8A and B). Both AMD and DEA caused concentration-dependent LDH release. Significant cytotoxicity was observed with AMD concentrations greater than 20 ug/ml and DEA concentrations greater than 7 ug/ml. Addition of TNF (3 ng/ml) did not cause cytotoxicity alone but significantly potentiated the cytotoxicity of AMD and DEA.

Neutralization of TNF In Vivo Attenuated AMD/LPS-Induced Liver Injury

Etanercept is a soluble TNF receptor construct that inactivates TNF. Etanercept (8 mg/kg, sc) injected 1 h before LPS inhibited the biological activity of TNF in rats and was not hepatotoxic by itself (Tukov et al., 2007; Zou et al., 2009a). The same treatment was used in this study. AMD/LPS cotreatment increased serum ALT activity, and etanercept significantly attenuated this increase (Fig. 9A). Changes in serum ALT activity were supported by histological

---

FIG. 3. Development of liver injury. Rats were treated with AMD (400 mg/kg, ip) or vehicle and 16 h later with LPS (1.6 × 10⁶ EU/kg, iv) or saline. They were examined 2, 4, 6, or 10 h after LPS injection. Activities of (A) ALT and (B) AST in serum were measured. # indicates significantly different from respective groups not given LPS; * indicates significantly different from respective group not given AMD. p < 0.05, n = 4–9.

FIG. 4. Markers of cholestasis after AMD/LPS cotreatment. Rats were treated with AMD (400 mg/kg, ip) or vehicle and 16 h later with LPS (1.6 × 10⁶ EU/kg, iv) or saline. Blood samples were collected at 10 h after LPS administration. Serum markers for cholestatic liver injury were measured: (A) ALP; (B) GGT; (C) concentration of total bile acids. # indicates significantly different from respective groups not given LPS; * indicates significantly different from respective group not given AMD. p < 0.05, n = 4–9.

FIG. 5. Hepatic histopathology. Rats were treated with AMD (400 mg/kg, ip) or vehicle and 16 h later with LPS (1.6 × 10⁶ EU/kg, iv) or saline. Liver tissue samples were collected at 10 h after LPS administration. Formalin-fixed liver samples were embedded in paraffin, sectioned, and stained with H&E staining. Treatment groups: (A) vehicle/sal; (B) vehicle/LPS; (C) AMD/sal; (D) AMD/LPS. CV, central vein; P, portal vein; C, capsule. Black arrows indicate fibrinopurulent capsulitis; * depicts necrotic foci. Inset in panel D is a higher magnification photomicrograph from a rat treated with AMD/LPS demonstrating neutrophils (white arrows).

---

FIG. 6. Development of liver injury. Rats were treated with AMD (400 mg/kg, ip) or vehicle and 16 h later with LPS (1.6 × 10⁶ EU/kg, iv) or saline. They were examined 2, 4, 6, or 10 h after LPS injection. Activities of (A) ALT and (B) AST in serum were measured. # indicates significantly different from respective groups not given LPS; * indicates significantly different from respective group not given AMD. p < 0.05, n = 4–9.
examination of H&E-stained liver sections: the severity and frequency of necrotic foci were markedly reduced in rats cotreated with etanercept (Fig. 9B).

DISCUSSION

Since its introduction in Europe in 1962, amiodarone has been associated with idiosyncratic hepatotoxicity (Lewis et al., 1989). A linear correlation between serum AMD concentration and serum ALT activities has been established (Pollak and You, 2003); however, in that study, the ALT values did not exceed 3 × ULN and were not considered to be clinically significant. For the cases of severe liver injury caused by intravenous amiodarone loading, patients’ serum ALT activities were up to 10–206 × ULN. There was usually a 24–72 h delay between the initial loading of AMD and the onset of elevation in ALT activities; and in many cases, the ALT activity returned to normal after a few days of continuation of maintenance dosing (Rätz Bravo et al., 2005). Accordingly, it is hard to draw a simple linear relationship between the magnitude or frequency of severe hepatotoxicity and serum AMD concentration. An effort to establish a model for AMD-induced liver injury in healthy rodents was unsuccessful. Neither short-term, large dose nor long-term, small dose administration of AMD led to observable liver damage (Young and Mehendale, 1989). The cause of severe AMD hepatotoxicity is more likely to be a combination of AMD and other factors, e.g., inflammatory...
episodes. In the present study, regardless of cotreatment with LPS, the serum concentration of AMD was about 1100 ng/ml, which is very close to the steady-state serum concentration of AMD in human patients (1500 ng/ml) under long-term oral amiodarone therapy (Pollak et al., 2000). Our findings support that at this clinically relevant concentration of AMD in serum, hepatotoxicity can be induced by a concurrent inflammatory episode related to LPS exposure.

Previous studies in rodents have suggested a possible association between inflammation and liver injury for several drugs associated with human IADRs, including chlorpromazine (Buchweitz et al., 2002), ranitidine (Luyendyk et al., 2003), diclofenac (Deng et al., 2006), trovafloxacin (Shaw et al., 2007), sulindac (Zou et al., 2009b), and halothane (Dugan et al., 2010). The results of the present study expand these findings and demonstrate that a nonhepatotoxic dose of AMD is rendered hepatotoxic when acute inflammation is triggered by LPS administration. Acute increases in serum markers for hepatocellular and cholestatic injury were found in rats cotreated with AMD/LPS. These resemble the clinical hepatic chemistry changes in human idiosyncrasy during AMD therapy (Rätz Bravo et al., 2005). The midzonal and bridging necrosis and infiltration of inflammatory cells in AMD/LPS are also consistent with some of the histological changes found in human patients (Babatin et al., 2008; Rätz Bravo et al., 2005). However, the histological characteristics in people with AMD-induced liver injury were variable. Different patterns of hepatocellular necrosis, such as midzonal, centrilobular, bridging, and panlobular, have been reported (Lewis et al., 1989). Genetic differences, concurrent medications, and even different origins of inflammation might account for these varied responses; nevertheless, the AMD/LPS interaction model in rats mimics important aspects of AMD-induced IADRs in human patients.

The timing of AMD and LPS dosing in this model was important for the development of severe liver damage. A minimal interval of 16 h was required for AMD and LPS to interact to induce liver injury. When LPS was injected within 16 h after AMD, no liver injury was observed. Absorption, distribution, metabolism, and clearance as well as toxicological actions could contribute to this timing requirement. The elimination of AMD is primarily through hepatic metabolism and biliary excretion, and its half-life in plasma is very long (55 days in humans) (Pollak et al., 2000). Accordingly, the loss of AMD due to elimination within 16 h is minimal. AMD has a dose-dependent effect on the respiratory chain and β-oxidation in the mitochondria (Fromenty et al., 1990a, b), and it can also affect the function of lysosomes and other acidic organelles (Stadler et al., 2008). The 16-h interval may be required for AMD to distribute into the liver, accumulate in organelles, and sensitize hepatocytes to interact with LPS or its downstream cytokines.

In other drug/LPS models, there is also a dependence on the temporal relationship between administrations of drug and LPS, and the time interval needed for a maximal hepatotoxic response is different for different drugs (Shaw et al., 2007; Zou et al., 2009b). This time interval requirement might help to explain the low frequency of IADRs in human patients; i.e., only when the inflammatory episode happens at a certain time during drug therapy would idiosyncratic hepatotoxicity occur.

In rats, AMD is deethylated by cytochromes P450 (CYPs) 3A4, 1A1, 2D1, and 2C11 in the liver (Elsherbiny et al., 2008). DEA, the major metabolite, is three- to fivefold more toxic than AMD to cultured HepG2 cells (Waldauser et al., 2006) and to primary rat hepatocytes (Gross et al., 1989). In our treatment of Hepa1c1c7 cells, a similar trend was observed (Fig. 8). The administration of LPS affects the expression and activities of CYPs in rats (Sewer et al., 1997). This raised the possibility that LPS might potentiate the toxicity of AMD by increasing its metabolism to DEA. To evaluate this, serum and liver concentrations of AMD and DEA were measured with LC/MS/MS. The average serum concentration of DEA in AMD-treated rats was 128 ng/ml, which is about 1/10 of the serum AMD concentration. This ratio is commonly seen in the serum after an intravenous loading dose of AMD, both in people (Ha et al., 2005) and rats (Shayeganpour et al., 2008). Neither the serum nor the liver concentration of AMD or DEA was affected by LPS cotreatment, suggesting that neither AMD accumulation nor DEA generation was affected by LPS.

Intratracheal instillation of AMD in vivo or exposure of alveolar macrophages to AMD in vitro led to TNF production (Putamura, 1996; Reinhart and Gairola, 1997). AMD treatment also increased TNF production by alveolar macrophages on LPS stimulation (Punithavathi et al., 2003). In the present study, treatment of rats with AMD alone did not cause serum TNF elevation, but it did increase the concentration of TNF in serum of LPS-treated rats. These results suggest that the increased appearance of TNF in AMD/LPS-cotreated rats was probably not an additive effect; rather, AMD appeared to potentiate the production or diminish the clearance of TNF caused by LPS. The concentration of TNF in serum increases rapidly in LPS-treated rats, peaks at around 1.5–2 h, and then returns to basal levels at around 6 h (Tukov et al., 2007). In the present study, the concentration of TNF around the peak time (i.e., 2 h) in LPS-cotreated rats was not affected by AMD, but the TNF concentration was greater in AMD-cotreated rats at a later time (4 h). These data suggest that AMD prolonged the elevation in TNF caused by LPS administration. This seemingly small difference in TNF concentration was shown to be critical to liver pathogenesis in another drug/LPS model of liver injury involving trovafloxacin (Shaw et al., 2009b). Accordingly, it is possible that prolongation of the LPS-induced TNF response is a critical event across models of LPS–drug interaction.

The importance of TNF in the AMD model was explored by preventing its binding to cellular receptors with etanercept. Etanercept pretreatment reduced hepatotoxicity, indicating that TNF has an important role in AMD/LPS-induced liver injury. Because no liver injury was observed after treatment with LPS
alone, the large TNF peak caused by LPS was not hepatotoxic by itself; however, this amount of TNF could be critical for the induction of hepatocellular injury by potentiating the toxic effect of AMD and/or DEA. Signaling from an activated TNF receptor can lead to lysosomal leakage, mitochondrial damage, and caspase activation (Wullaert et al., 2007). All three of these events were also found in AMD and DEA cytotoxicity in vitro (Agoston et al., 2003; Spaniol et al., 2001). Further support for a critical role for TNF came from our in vitro study in Hepa1c1c7 cells in which TNF increased the cytotoxicity of both AMD and DEA. As a proximal proinflammatory cytokine, TNF can also contribute to liver damage by inducing downstream inflammatory events, such as coagulation activation and neutrophil activation (Shaw et al., 2009b; Tukov et al., 2007).

The etanercept treatment herein reduced the ALT activity to half of the level seen in the absence of this inhibitor, whereas the same dose of etanercept reduced the ALT activity almost to control level in trovafloxacin/LPS and sulindac/LPS models (Shaw et al., 2007; Zou et al., 2009a). This suggests that other factors induced by LPS might act in parallel with TNF in the AMD/LPS model. In other models of potentiation of xenobiotic toxicity by LPS, factors such as neutrophils (Luyendyk et al., 2005), the coagulation system (Shaw et al., 2009a), and prostanoids (Ganey et al., 2001) play important roles, and these factors might be relevant in the model presented here.

In summary, AMD was rendered hepatotoxic in rats in the presence of a coexisting inflammatory stress induced by LPS. AMD/LPS-coexposed animals developed liver pathology and blood chemistry changes that resemble AMD-induced idiosyncratic hepatotoxicity in human patients. LPS did not interact with AMD by changing the metabolism or distribution of AMD. AMD enhanced the increase in plasma TNF concentration caused by LPS, and neutralizing TNF reduced liver injury from AMD/LPS coexposure. Moreover, TNF potentiated the cytotoxicity of both AMD and DEA in vitro. These findings add support to the idea that inflammatory stress can interact with IADR-associated drugs to cause liver injury by a mechanism involving TNF and suggest that a similar mode of action might apply to several drugs that cause idiosyncratic hepatotoxicity in humans.

FUNDING

National Institutes of Health (R01DK061315).

REFERENCES

Agoston, M., Orsi, F., Feher, E., Hagymasi, K., Orosz, Z., Blazovics, A., Feher, J., and Vereckei, A. (2003). Silymarin and vitamin E reduce amiodarone-induced lysosomal phospholipidosis in rats. Toxicology 190, 231–241.

Babatin, M., Lee, S. S., and Pollak, P. T. (2008). Amiodarone hepatotoxicity. Curr. Vasc. Pharmacol. 6, 228–236.

Beutler, B., and Kruys, V. (1995). Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself. J. Cardiovasc. Pharmacol. 25(Suppl. 2), S1–S8.

Buchweitz, J. P., Ganey, P. E., Bursian, S. J., and Roth, R. A. (2002). Underlying endotoxemia augments toxic responses to chlorpromazine: Is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther. 300, 460–467.

Deng, X., Stachlewitz, R. F., Liguori, M. J., Blomme, E. A., Waring, J. F., Luyendyk, J. P., Maddox, J. F., Ganey, P. E., and Roth, R. A. (2006). Modest inflammation enhances diclofenac hepatotoxicity in rats: Role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther. 319, 1191–1199.

Dugan, C. M., MacDonald, A. E., Roth, R. A., and Ganey, P. E. (2010). A mouse model of severe halothane hepatitis based on human risk factors. J. Pharmacol. Exp. Ther. 333, 364–372.

Elscherbiny, M. E., El-Kadi, A. O., and Brooks, D. R. (2008). The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J. Pharmacokin. Pharmacodyn. Sci. 11, 147–159.

Fromenty, B., Fisch, C., Berson, A., Letteron, P., Larrey, D., and Pessaye, D. (1990a). Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J. Pharmacol. Exp. Ther. 255, 1377–1384.

Fromenty, B., Fisch, C., Labbe, G., Degott, C., Deschamps, D., Berson, A., Letteron, P., and Pessaye, D. (1990b). Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J. Pharmacol. Exp. Ther. 255, 1371–1376.

Futamura, Y. (1996). Effect of amiodarone on cytokine release and on enzyme activities of mouse alveolar macrophages, bone marrow macrophages, and blood monocytes. J. Toxicol. Sci. 21, 125–134.

Ganey, P. E., Barton, Y. W., Kinser, S., Sneed, R. A., Barton, C. C., and Roth, R. A. (2001). Involvement of cyclooxygenase-2 in the potentiation of allyl alcohol-induced liver injury by bacterial lipopolysaccharide. Toxicol. Appl. Pharmacol. 174, 113–121.

Gross, S. A., Bandyopadhyay, S., Klaunig, J. E., and Somani, P. (1989). Amiodarone and desethylamiodarone toxicity in isolated hepatocytes in culture. Proc. Soc. Exp. Biol. Med. 190, 163–169.

Ha, H. R., Bigler, L., Wendt, B., Maggiorini, M., and Follath, F. (2005). Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients. Eur. J. Pharm. Sci. 24, 271–279.

Lewis, J. H., Ranard, R. C., Caruso, A., Jackson, L. K., Mullick, F., Ishak, G. K., Seef, L. B., and Zimmerman, H. J. (1989). Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology 9, 679–685.

Luyendyk, J. P., Maddox, J. F., Cosma, G. N., Ganey, P. E., Cockerell, G. L., and Roth, R. A. (2003). Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 307, 9–16.

Luyendyk, J. P., Shaw, P. J., Green, C. D., Maddox, J. F., Ganey, P. E., and Roth, R. A. (2005). Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J. Pharmacol. Exp. Ther. 314, 1023–1031.

O’Sullivan, J. J., McCarthy, P. T., and Wren, C. (1995). Differences in amiodarone, digoxin, flecainide and sotalol concentrations between antemor- tem serum and femoral postmortem blood. Hum. Exp. Toxicol. 14, 605–608.

Pollak, P. T., Bouillon, T., and Shafer, S. L. (2000). Population pharmacokinetics of long-term oral amiodarone therapy. Clin. Pharmacol. Ther. 67, 642–652.

Pollak, P. T., and You, Y. D. (2003). Monitoring of hepatic function during amiodarone therapy. Am. J. Cardiol. 91, 613–616.

Punithavathi, D., Venkatesan, N., and Babu, M. (2003). Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. Br. J. Pharmacol. 139, 1342–1350.
Rätz Bravo, A. E., Drewe, J., Schienger, R. G., Krähenbühl, S., Pargger, H., and Ummenhofer, W. (2005). Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. *Crit. Care Med.* **33**, 128–134.

Reinhart, P. G., and Gairola, C. G. (1997). Amiodarone-induced pulmonary toxicity in Fischer rats: Release of tumor necrosis factor alpha and transforming growth factor beta by pulmonary alveolar macrophages. *J. Toxicol. Environ. Health* **52**, 353–365.

Roth, R. A., Luyendyk, J. P., Maddox, J. F., and Ganey, P. E. (2003). Inflammation and drug idiosyncrasy—is there a connection? *J. Pharmacol. Exp. Ther.* **307**, 1–8.

Rotmensch, H. H., Belhassen, B., Swanson, B. N., Shoshani, D., Spielman, S. R., Greenspan, A. J., Greenspan, A. M., Vlasses, P. H., and Horowitz, L. N. (1984). Steady-state serum amiodarone concentrations: Relationships with antiarrhythmic efficacy and toxicity. *Ann. Intern. Med.* **101**, 462–469.

Sewer, M. B., Koop, D. R., and Morgan, E. T. (1997). Differential inductive and suppressive effects of endotoxin and particulate irritants on hepatic and renal cytochrome P-450 expression. *J. Pharmacol. Exp. Ther.* **280**, 1445–1454.

Shaw, P. J., Fullerton, A. M., Scott, M. A., Ganey, P. E., and Roth, R. A. (2009a). The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. *Toxicol. Pharmacol.** **236**, 293–300.

Shaw, P. J., Ganey, P. E., and Roth, R. A. (2009b). Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/ lipopolysaccharide coexposure. *J. Pharmacol. Exp. Ther.* **328**, 62–68.

Shaw, P. J., Hopfensperger, M. J., Ganey, P. E., and Roth, R. A. (2007). Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. *Toxicol. Sci.* **100**, 259–266.

Shayeghanpour, A., Hamdy, D. A., and Brocks, D. R. (2008). Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. *Biopharm. Drug Dispos.* **29**(3), 159–166.

Singh, B. N. (1996). Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. *Am. J. Cardiol.* **78**, 41–53.

Spaniol, M., Bracher, R., Ha, H. R., Follath, F., and Krähenbühl, S. (2001). Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. *J. Hepatol.* **35**, 628–636.

Stadler, K., Ha, H. R., Cininale, V., Spiri, C., Saletti, G., Schiavon, M., Bruttonesso, D., Bigler, L., Follath, F., Pettenazzo, A., and Baritussio, A. (2008). Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. *Am. J. Respir. Cell Mol. Biol.* **39**, 142–149.

Talajic, M., DeRooide, M. R., and Nattel, S. (1987). Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: Evidence for clinically relevant activity of the metabolite. *Circulation* **75**, 265–271.

Teoh, N., Field, J., Sutton, J., and Farrell, G. (2004). Dual role of tumor necrosis factor-alpha in hepatic ischemia-reperfusion injury: Studies in tumor necrosis factor-alpha gene knockout mice. *Hepatology* **39**, 412–421.

Tukov, F. F., Luyendyk, J. P., Ganey, P. E., and Roth, R. A. (2007). The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. *Toxicol. Sci.* **100**, 267–280.

Uetrecht, J. (2007). Idiosyncratic drug reactions: Current understanding. *Annu. Rev. Pharmacol. Toxicol.* **47**, 513–539.

Waldhauser, K. M., Török, M., Ha, H. R., Thomet, U., Konrad, D., Brecht, K., Follath, F., and Krähenbühl, S. (2006). Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. *J. Pharmacol. Exp. Ther.* **319**, 1413–1423.

Waring, J. F., Liguori, M. J., Luyendyk, J. P., Maddox, J. F., Ganey, P. E., Stachlewitz, R. F., North, C., Blomme, E. A., and Roth, R. A. (2006). Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. *J. Pharmacol. Exp. Ther.* **316**, 1080–1087.

Wullaert, A., van Loo, G., Heyninck, K., and Beyaert, R. (2007). Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: Effects on liver homeostasis and beyond. *Endocr. Rev.* **28**, 365–386.

Yin, M., Wheeler, M. D., Kono, H., Bradford, B. U., Gallucci, R. M., Luster, M. I., and Thuman, R. G. (1999). Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. *Gastroenterology** **117**, 942–952.

Young, R. A., and Mehendale, H. M. (1989). Effects of short-term and long-term administration of amiodarone on hepatobiliary function in male rats. *J. Appl. Toxicol.* **9**, 407–412.

Zou, W., Beggs, K. M., Sparkenbaugh, E. M., Jones, A. D., Younis, H. S., Roth, R. A., and Ganey, P. E. (2009a). Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury. *J. Pharmacol. Exp. Ther.* **331**, 114–121.

Zou, W., Devi, S. S., Sparkenbaugh, E., Younis, H. S., Roth, R. A., and Ganey, P. E. (2009b). Hepatotoxic interaction of sulindac with lipopolysaccharide: Role of the hemostatic system. *Toxicol. Sci.* **108**, 184–193.